Opendata, web and dolomites

TRACE SIGNED

Transfer of multivirus-specific T-cells following transplantation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRACE project word cloud

Explore the words cloud of the TRACE project. It provides you a very rough idea of what is the project "TRACE" about.

life    milestone    stem    immunity    trace    physiological    human    trial    cellular    options    personalized    receiving    time    trials    diseases    deficient    cmv    manufacturing    hurdles    adenovirus    daily    unsolved    efficacy    prospective    epstein    threatening    restored    prove    virus    survival    overcome    health    clinical    barr    lack    standard    infection    limited    saving    adv    adoptive    refractory    individualized    structural    cell    translation    industrial    immunotherapy    routine    allogeneic    expertise    infections    post    proven    transplantation    regulatory    national    qualification    safe    safety    none    medicine    procedure    agents    breakthrough    body    thereby    variety    excellence    standardized    transfer    instead    gmp    protective    viral    facilities    intensive    self    rare    immune    quality    patients    ebv    individuals    toxic    hsct    first    lacking    curative    protection    compromized    treatment    sct    economics    cytomegalovirus    basic   

Project "TRACE" data sheet

The following table provides information about the project.

Coordinator
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN 

Organization address
address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539
website: www.uni-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.trace-study.de
 Total cost 6˙000˙000 €
 EC max contribution 6˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) coordinator 1˙641˙600.00
2    ORION CLINICAL SERVICES LTD UK (SLOUGH) participant 2˙099˙005.00
3    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY FR (NANCY CEDEX) participant 507˙570.00
4    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 442˙025.00
5    Universitair Ziekenhuis Gent BE (Gent) participant 401˙550.00
6    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 350˙600.00
7    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 349˙725.00
8    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 207˙925.00

Map

 Project objective

Allogeneic stem cell transplantation (HSCT) is a curative treatment for a variety of diseases. Viral infections such as Cytomegalovirus (CMV), Epstein-Barr-virus (EBV) and Adenovirus (AdV) are major unsolved problems for patients receiving allogeneic HSCT. Refractory viral infections post-HSCT are rare, life-threatening conditions due to the deficient T-cell response post-SCT and lacking effective treatment options. Protective T-cell immunity could be restored by means of a procedure known as adoptive T-cell transfer. Although cellular immunotherapy is considered a major recent breakthrough in medicine, none of the cellular treatment approaches has yet become a standard treatment. The reason for this limited translation into daily clinical practice is the lack of controlled, prospective clinical trials investigating efficacy of immunotherapy. The objective of TRACE is to bring adoptive T-cell transfer into clinical routine as a life-saving, curative and safe treatment for refractory viral infection post-HSCT. TRACE is a multi-national clinical trial to prove efficacy and safety of adoptive T-cell transfer in immune-compromized individuals. For the first time, this trial will show that a unique individualized immunotherapy could be included into evidence based clinical routine in rare diseases. Regulatory and structural hurdles will be overcome by standardized GMP-procedures. It will be a major milestone in the development of medicine and health economics to bring such a unique personalized treatment approach into a clinical efficacy trial. The consortium provide excellence in immunotherapy through partners from basic, clinical and industrial research and GMP facilities, with proven qualification and expertise in the field of HSCT, GMP manufacturing and adoptive T-cell transfer. It will bring medicine towards physiological self-protection of the human body instead of cost-intensive toxic agents and will thereby improve survival and quality of life.

 Deliverables

List of deliverables.
Individualized press release for every partner Documents, reports 2020-04-07 22:49:03
Registration number of clinical study in a WHO- or ICMJE-approved registry Documents, reports 2020-04-07 22:49:03
Final version of study protocol as approved by first regulatory/ethics committee (Package 1) Documents, reports 2020-04-07 22:49:03
Launch of website and social media account Websites, patent fillings, videos etc. 2020-04-07 22:49:03
Plan for the analysis of the functional activity of the multivirus-specific T cell product Documents, reports 2020-04-07 22:49:03
SOP for immune monitoring of patient samples Documents, reports 2020-04-07 22:49:03
Site selection Documents, reports 2020-04-07 22:49:03

Take a look to the deliverables list in detail:  detailed list of TRACE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Theresa Kaeuferle, Ramona Krauss, Franziska Blaeschke, Semjon Willier, Tobias Feuchtinger
Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation
published pages: 12-13, ISSN: 1756-8722, DOI: 10.1186/s13045-019-0701-1
Journal of Hematology & Oncology 12/1 2020-04-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More